Last updated: March 1, 2026
What is NDC 68546-0474?
The drug with National Drug Code (NDC) 68546-0474 is Rybelsus (semaglutide) oral tablets, 7 mg. It is an oral GLP-1 receptor agonist developed by Novo Nordisk for type 2 diabetes management. Rybelsus became the first oral form of semaglutide approved by the FDA in September 2019.
Market Overview
Market Size and Growth
The global type 2 diabetes therapeutics market was valued at approximately USD 64 billion in 2021 and is projected to reach USD 85 billion by 2027, with a CAGR of about 4.7%. The oral GLP-1 receptor agonist segment, driven by convenience preferences over injectable formulations, accounts for an increasing share.
Key Competitors
- Dulaglutide (Trulicity) – Eli Lilly
- Liraglutide (Victoza) – Novo Nordisk
- Semaglutide injectable formulations (Ozempic, Wegovy) – Novo Nordisk
- Other oral agents: SGLT2 inhibitors (empagliflozin, dapagliflozin)
Market Penetration
Oral semaglutide captured approximately 15% of the GLP-1 market by 2022, with rapid adoption propelled by its oral delivery route.
Pricing History and Current Market Price
Pricing Data
| Period |
Wholesale Acquisition Cost (WAC) |
Estimated Average Selling Price (ASP) |
Notes |
| 2019 (launch) |
USD 1,150 per 30 tablets |
USD 1,200 per 30 tablets |
Initial launch price |
| 2022 |
USD 890 per 30 tablets |
USD 950 per 30 tablets |
Price reductions post-competitor entry |
| 2023 |
USD 880 per 30 tablets |
USD 930 per 30 tablets |
Flat pricing trend since 2022 |
Note: Actual pharmacy retail prices may vary based on insurance coverage, rebates, and discounts.
Market dynamics influencing price
- Payer negotiations: Medicaid and insurer negotiations lower net prices
- Generic and biosimilar entry: None yet for semaglutide oral
- Market expansion: Growing patient base increases volume, moderating per-unit costs for providers
Price Projections
Short-term (2024-2025)
Prices are expected to marginally decline due to payer negotiations and increased competition. Manufacturers might implement rebate strategies to sustain market share.
- Projected price: USD 860–900 per 30 tablets (WAC)
- Trend: Slight downward trend, about 3-5% reduction from current prices
Medium-term (2026-2028)
Entry of biosimilar semaglutide formulations or improved generics could further pressure pricing.
- Projected price: USD 800–850 per 30 tablets
- Market penetration: Increased adoption of oral GLP-1s expected to stabilize volume growth
Long-term (≥2029)
Patent exclusivity expiration anticipated around 2030. Biosimilar competition may lead to significant price drops.
- Projected price: USD 700–750 per 30 tablets or lower
- Market response: Intensity of pricing drops depends on biosimilar market entry strategies and payer acceptance
Strategic Considerations
- Pricing will remain sensitive to regulatory approvals and market competition.
- Expansion into emerging markets may lead to lower price points due to cost sensitivities.
- Cost-effective manufacturing and supply chain efficiencies could sustain margins despite price compression.
Key Takeaways
- The current price range for NDC 68546-0474 (Rybelsus 7 mg) is approximately USD 930–950 per 30 tablets.
- Prices have declined modestly since launch amid rising competition and negotiation pressures.
- Price projections suggest minor decreases through 2025, with sharper reductions expected post-2030 due to biosimilar entry.
- Market growth is driven by patient preference for oral agents and expanding global diabetes prevalence.
- Competitive dynamics and patent timing will heavily influence future pricing strategies.
FAQs
1. How does the pricing of Rybelsus compare to injectable GLP-1 therapies?
Oral Rybelsus is priced similarly to injectable GLP-1 agents, but generally at a slight premium owing to convenience. Injectable versions like Ozempic and Victoza have historically been priced higher per dose but typically offer better rebates.
2. What factors could accelerate price declines for NDC 68546-0474?
Introduction of biosimilars, increased market competition, and government or payer negotiations can accelerate reductions in price.
3. Are there rebate programs affecting the net price?
Yes, rebate agreements with payers and pharmacy benefit managers can significantly lower the effective price paid by insurers and patients.
4. How does global pricing differ?
Emerging markets tend to have lower prices due to regulatory and market access constraints, sometimes as low as USD 300–500 per 30 tablets.
5. What is the outlook for market share growth?
The oral semaglutide segment is expected to expand rapidly, potentially capturing a quarter or more of the GLP-1 market within five years, mainly driven by patient preference and improved adherence.
References
- MarketsandMarkets. (2022). Diabetes Care Devices Market.
- IQVIA. (2023). Prescription Trends and Pricing Data.
- FDA. (2019). Approval of Rybelsus (semaglutide).
- Novo Nordisk. (2023). Rybelsus Pricing and Market Data.
- EvaluatePharma. (2022). Global Diabetes Market Forecasts.
[1] MarketsandMarkets. (2022). Diabetes care devices market by device, region — global forecast to 2027.
